The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Longitudinal safety of liso-cel in patients with second-line or later large B-cell lymphoma
In this interview, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, provides insight into the longitudinal safety of lisocabtagene maraleucel (liso-cel) in 420 patients with second-line or later large B-cell lymphoma (LBCL), treated in the TRANSFORM (NCT03575351), PILOT (NCT03483103), or TRANSCEND NHL 001 (NCT02631044) clinical trials. Dr Kamdar highlights the favorable long-term safety of liso-cel in this patient population, with data reinforcing the feasibility of outpatient management and assuring community physicians that patients can return to their care around day 15 post-infusion if they are doing well. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
